|Title:||Antiviral Therapy in Patients With Chronic Hepatitis C Is Associated With a Reduced Risk of Parkinsonism||Authors:||TUNG-HUNG SU
|Issue Date:||2019||Publisher:||John Wiley and Sons Inc.||Journal Volume:||34||Journal Issue:||12||Start page/Pages:||1882-1890||Source:||Movement Disorders||Abstract:||
Background: The risk of parkinsonism after antiviral treatment against chronic hepatitis C (CHC) is unclear. Objectives: To investigate the association between CHC and parkinsonism and the efficacy of antiviral therapy. Methods: Using the National Health Insurance Research Database of Taiwan from 2004 to 2012, patients with and without CHC, patients receiving pegylated interferon-based antiviral therapy, and those without such therapy were matched by age, gender, and comorbidities by propensity scores and followed for new diagnoses of parkinsonism and Parkinson's disease (PD). Multivariable Cox proportional hazards regression analyses were performed. Results: Overall, 49,342 patients with CHC were matched with 49,342 non-CHC patients. After adjustment for confounding factors, there was a significantly increased risk (31%) of parkinsonism (hazard ratio [HR] 1.306; 95% confidence interval [CI], 1.208–1.412) in those with CHC and the risk of parkinsonism requiring anti-Parkinson medication (HR 1.323; 95% CI, 1.214–1.441). Furthermore, 23,647 untreated CHC patients were matched with 23,647 patients receiving antiviral therapy. Patients receiving antiviral therapy had a significantly lower risk of developing parkinsonism (38%; HR 0.618; 95% CI, 0.498–0.765) and a reduced risk of parkinsonism requiring anti-Parkinson medication (HR 0.651; 95% CI, 0.515–0.823). In sensitivity analyses, antiviral therapy significantly reduced the risk of parkinsonism and PD after adjustment for detection, selection, disease latency biases, and competing mortality. Our results suggest successful antiviral therapy associates with a reduced risk of hepatitis C virus–related parkinsonism compared with those with treatment failure. Conclusions: CHC infection is associated with an increased risk of parkinsonism or PD. Antiviral therapy against CHC is associated with a reduced risk of parkinsonism or PD. ? 2019 International Parkinson and Movement Disorder Society. ? 2019 International Parkinson and Movement Disorder Society
|ISSN:||0885-3185||DOI:||10.1002/mds.27848||SDG/Keyword:||antiparkinson agent; antivirus agent; liver protective agent; peginterferon alpha2a plus ribavirin; peginterferon alpha2b plus ribavirin; alpha interferon; antivirus agent; macrogol; peginterferon alpha2a; recombinant protein; adult; antiviral therapy; Article; chronic hepatitis C; cohort analysis; comorbidity; controlled study; female; follow up; human; incidence; major clinical study; male; middle aged; parkinsonism; population research; priority journal; risk reduction; aged; chronic hepatitis C; complication; parkinsonism; risk; treatment outcome; Adult; Aged; Antiviral Agents; Cohort Studies; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Parkinsonian Disorders; Polyethylene Glycols; Recombinant Proteins; Risk; Treatment Outcome
|Appears in Collections:||醫學系|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.